Skip to main content
SpringerLink
Log in

MULTIPLE SCLEROSIS

How common is active inflammation in progressive multiple sclerosis?

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

In patients with progressive multiple sclerosis, the presence of active inflammation is associated with improved efficacy of anti-inflammatory therapies. However, the frequency of active inflammation in this patient population is unknown, and is the subject of a new study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dangond, F. et al. Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal. Nat. Rev. Neurol. 17, 185–192 (2021).

    Article  Google Scholar 

  2. Kappos, L. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391, 1263–1273 (2018).

    Article  CAS  Google Scholar 

  3. Hawker, K. et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460–471 (2009).

    Article  CAS  Google Scholar 

  4. Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209–220 (2017).

    Article  CAS  Google Scholar 

  5. Lublin, F. D. et al. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology 94, 1088–1092 (2020).

    Article  Google Scholar 

  6. Mathey, G. et al. Clinical and radiological activity of secondary progressive multiple sclerosis in a population-based cohort. Eur. J. Neurol. https://doi.org/10.1111/ene.14861 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

    Robert J. Fox

Authors
  1. Robert J. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert J. Fox.

Ethics declarations

Competing interests

R.J.F. has received personal consulting fees from AB Science, Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, Sanofi and TG Therapeutics; served on advisory committees for Actelion, Biogen, Immunic, Novartis and Sanofi; and received clinical trial contract and research grant funding from Biogen, Novartis and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fox, R.J. How common is active inflammation in progressive multiple sclerosis?. Nat Rev Neurol 17, 463–464 (2021). https://doi.org/10.1038/s41582-021-00518-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-021-00518-4

  • Springer Nature Limited

Search

Navigation